REGENXBIO INC (RGNX) Stock Analyst Ratings
USA - NASDAQ:RGNX - US75901B1070 - Common Stock
12.77 USD
-0.05 (-0.39%)
12.77 USD
0 (0%)
ChartMill assigns a Buy % Consensus number of 84% to RGNX. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 31.86. This target is 149.46% above the current price.
RGNX was analyzed by 19 analysts. The buy percentage consensus is at 84. So analysts seem to be very confident about RGNX.
In the previous month the buy percentage consensus was at a similar level.
RGNX was analyzed by 19 analysts, which is quite many. So the average rating should be quite meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2025-10-07 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-09-08 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-09-08 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-08-19 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-08-08 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-08-08 | RBC Capital | Maintains | Outperform -> Outperform |
| 2025-08-08 | Barclays | Maintains | Overweight -> Overweight |
| 2025-06-09 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-04-17 | Goldman Sachs | Maintains | Neutral -> Neutral |
| 2025-03-21 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-20 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-03-20 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2025-03-17 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2025-03-14 | Chardan Capital | Maintains | Buy -> Buy |
| 2025-03-14 | Morgan Stanley | Maintains | Overweight -> Overweight |
| 2025-02-11 | Goldman Sachs | Downgrade | Buy -> Neutral |
| 2025-01-21 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2025-01-15 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-12-11 | RBC Capital | Reiterate | Outperform -> Outperform |
| 2024-11-21 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-11-20 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-11-07 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-10-22 | Chardan Capital | Maintains | Buy -> Buy |
| 2024-10-10 | Raymond James | Reiterate | Outperform |
| 2024-09-04 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-08-05 | Barclays | Maintains | Overweight -> Overweight |
| 2024-08-05 | HC Wainwright & Co. | Maintains | Buy -> Buy |
| 2024-06-20 | HC Wainwright & Co. | Reiterate | Buy -> Buy |
| 2024-06-07 | Goldman Sachs | Initiate | Buy |
| 2024-05-15 | HC Wainwright & Co. | Maintains | Buy -> Buy |
REGENXBIO INC / RGNX FAQ
What is the average price target for REGENXBIO INC (RGNX) stock?
19 analysts have analysed RGNX and the average price target is 31.86 USD. This implies a price increase of 149.45% is expected in the next year compared to the current price of 12.77.
How do analysts rate REGENXBIO INC (RGNX)?
The consensus rating for REGENXBIO INC (RGNX) is 84.2105 / 100 . This indicates that analysts generally have a positive outlook on the stock.
How many analysts have analysed REGENXBIO INC (RGNX)?
The number of analysts covering REGENXBIO INC (RGNX) is 19.